Skip to Main Content

Genitourinary Medical Oncology Clinic

The UCSF Genitourinary Medical Oncology Clinic is home to some of the country's leading specialists in cancers of the genital and urinary systems. We provide the full spectrum of care, including screening exams, transrectal ultrasound and biopsy, diagnostic imaging, second opinions and treatments ranging from surgery to radiation therapy.

The clinic also offers education and support groups. In addition, patients may have access to the latest experimental therapies by participating in clinical trials.

Learn more about clinical trials and how they work.

Our locations

Expand Map

    Other UCSF cancer care options near you (2)

    UCSF-John Muir Health Cancer Center in Berkeley

    UCSF-John Muir Health Cancer Center in Berkeley

    3100 San Pablo Ave., Suite 280
    Berkeley, CA 94702

    2

    UCSF – Washington Cancer Center

    UCSF – Washington Cancer Center

    See our locations in Fremont.

    Decorative Caduceus

    Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

    rPFS is defined as the amount of time from the initiation of study therapy and the day of first documented radiographic disease progression per RECIST version 1.1 and PCWG3 criteria. The proportion of patients without radiographic...

    Recruiting

    Decorative Caduceus

    FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prost...

    Frequencies and percentages of participants with TEAEs will be summarized. Analysis will also be completed regarding duration of TEAEs and their severity.

    Recruiting

    Decorative Caduceus

    Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer ...

    The time from randomization to first documentation of disease progression per RECIST v1.1 by BICR, or to death due to any cause.

    Recruiting

    Decorative Caduceus

    Phase 1 Trial of RP-3467 Alone and in Combination with Olaparib in Participants with Advanced S...

    Incidence and severity of treatment-emergent adverse events (TEAEs) as assessed per NCI CTCAE v5.0 criteria

    Recruiting

    Decorative Caduceus

    ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate ...

    Incidence and severity of adverse events or serious adverse events of ARX517 alone or in combination with ARPIs will be assessed to determine the safety and tolerability of the treatment using National Cancer Institute (NCI) Commo...

    Recruiting

    Decorative Caduceus

    Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    Recruiting

    Decorative Caduceus

    A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HE...

    The proportion of participants with confirmed complete response (CR) or partial response (PR) according to RECIST v1.1

    Recruiting

    Decorative Caduceus

    Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer

    The Decisional Conflict Scale measures personal perceptions of : a) uncertainty in choosing options; b) modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in de...

    Recruiting

    Decorative Caduceus

    Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Canc...

    The RP2D is the last dose cohort at which no more than one instance of a dose limiting toxicity (DLT) is observed among 6 participants treated. If the maximum tolerated dose (MTD) cannot be determined due to lack of DLT during the...

    Recruiting

    Decorative Caduceus

    Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With So...

    On overall response will be reported as a percentage of participants with a complete response (CR) or partial response (PR) as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Recruiting

    Rankings & achievements

    • U S  News and World Report badge recognizing UCSF as part of its 2024-2025 Honor Roll

      Among the top hospitals in the nation

    • Best in Northern California and No. 7 in the nation for cancer care

    • Best in Northern California for urology

    • Rated high-performing hospital for colon cancer surgery

    • n1-2x

      in NIH funding for urology research

    Accreditations & memberships

    • National Cancer Institute

      The National Cancer Institute has designated UCSF a comprehensive cancer center, its highest ranking. This designation is awarded to centers that demonstrate scientific excellence and the ability to conduct cancer research across many disciplines.

    • Commission on Cancer

      UCSF's cancer programs have been accredited by the American College of Surgeons' Commission on Cancer (CoC) since 1933. The CoC is a consortium of groups dedicated to improving cancer patients' survival and quality of life via research, education and better medical care.

    • National Comprehensive Cancer Network

      UCSF is a member of the National Comprehensive Cancer Network, an alliance of the world’s top cancer centers. The network brings together leaders in treatment and research to improve the quality, effectiveness and efficiency of cancer care.

    Support services

    Preparing for your appointment

    What to Bring

    • Recent radiology reports and images including X-ray, MRI and ultrasound films or CDs –that relate to your condition
    • Pathology reports of any biopsies or tests. Please bring glass pathology slides from the lab or office where the test was performed.
    • Copies of all records relevant to your condition, including your last laboratory report and the most recent report or dictation from the doctor who referred you to UCSF. These items may include records from your primary care physician, oncologist or surgeon.
    • Copies of your insurance cards
    • A list of all your doctors, including their mailing addresses, telephone numbers and fax numbers

    Related clinics

    Our research initiatives

    • UCSF-Helen-Diller-Family-Comprehensive-Cancer-Center-Research-2x

      UCSF Helen Diller Family Comprehensive Cancer Center Research

      UCSF is home to a range of research initiatives aimed at improving outcomes for cancer patients everywhere. This includes research on topics such as immunotherapy, BRCA mutations and molecular diagnostic testing.

    Can't find what you're looking for?

    UCSF Help Center

    (888) 689-8273

    Share